A placebo-controlled trial of thymic hormone treatment of recurrent herpes simplex labialis infection in immunodeficient hosts.
Twenty-one immunodeficient patients with recurrent herpes simplex labialis (HSL) were randomly allocated to either saline or the bovine thymus extract thymostimulin (TS) and treated for a period of 6 months. An impressive reduction in both number and severity of the recurrences of the infection was observed in TS-treated patients during the trial and for up to 3 months afterward. A significant increase in total WBC, lymphocyte count, and T cells was detected in the TS group after 6 months. In vitro lymphoproliferative responses to herpes simplex virus antigen and natural killer cell activity were also significantly higher in the TS group, whereas no significant difference in antibody titers to herpes simplex could be detected between the two groups. TS can therefore help prevent viral reactivation in immunocompromised hosts by potentiating cell-mediated immune responses and should be considered for use in prophylaxis of infection in patients at risk and also in apparently normal subjects with recurrent HSL.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005260:Female; D006560:Herpes Labialis / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008297:Male; D010919:Placebos; D011897:Random Allocation; D012008:Recurrence; D013949:Thymus Extracts / Q000009:adverse effects / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D010919:Placebos; D013949:Thymus Extracts